Uveitis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

  • Single User License $3500

Uveitis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

Status : March, 2020 | Pharmaceutical | PPT format

Report Digest


Global Uveitis Drugs Market: Overview 

A limited choice of commercial drugs composed of corticosteroid treatments, immunosuppresives and biologics is characteristic of the global uveitis drugs market. Uveitis (Uveitis) is a median eye inflammation (Uvea) known as the uvea tract. The uvea is made up of iris, ciliary and choroids. Certain prevalent causes of uveitis are autoimmune diseases, infection, injury, inflammatory diseases and surgeries. Uveitis-related common symptoms include eye pain, floating eye conditions, blurred vision, enhanced light sensitivity and redness in the eye. Uveitis happens in all age groups, but it mostly involves people aged 20 to 59. Corticoid therapy has historically formed the majority of global uveitis drugs market. 

This market intelligence study on the global uveitis drugs market focusses on the prominent drivers impacting growth, market trend, possibilities, and limitations, if any. The report offers actionable insights on the key determinants and competitive landscape of the global uveitis drugs market. 

Global Uveitis Drugs Market: Notable Developments 

Some of the key developments influencing the global uveitis drugs market include: 

  • Newer drugs are in the pipeline and will be launched at the end of 2019. Santen Pharmaceutical Co is produced under the pipeline DE-109 (phase III) (sirolimus). The product is allocated to treat post-infectious uveitis as an orphan drug by the U.S. and EU regulatory bodies. The method of sterile formulation is very difficult and businesses are inclined to align their products with GMP and regulatory rules. The emergence of novel drugs is likely to bode well for the global uveitis drugs market. 
  • In Asia-Pacific, AbbVie's Humira (adalimumab) is the only target treatment which is currently accessible. The uvéitis pipeline is comprised of CLS-TA, which should be extremely profitable and meet some of the unmet requirements of Santen's Opsiria and Clearside Biomedical. These new pharmaceutical products will expand possibilities for uveitis patients by providing new methods of therapy, including drug new delivery routes and new non-corticosteroid medication molecules. This is expected to fuel the global uveitis drugs market as well. 

Some of the most prominent competitors operating in the competitive landscape of global uveitis drugs market include –

  • Allergan India Private Limited
  • Topivert Ltd
  • Bausch & Lomb Incorporated
  • pSivida Corp.
  • HANALL
  • Ophthalix Inc.
  • XOMA,
  • AbbVie Inc

Global Uveitis Drugs Market Growth Dynamics 

Increased aging population, increasing incidence of uveitis and associated complications have led to significant development of the global market for uveitis drugs. In addition, the implementation, rapid approval of pipeline drugs, increased investments in research and development into pharmaceuticals, and increasing public measures to minimize eye disorders also contribute to the growth of the global uveitis drugs market. Another important driver for the uveitis industry is the introduction of new drug delivery routes to improve the effectiveness of the drug. 

Nevertheless, adverse effects of uveitis therapy drugs, such as watery eyes, irritations and others, could hinder development of the global uveitis drugs market. The market for uveitis drugs is likely to be further hampered by poor primary healthcare facilities, lack of knowledge of eye conditions, and an absence of health insurance in developing nations. 

Asia Pacific to Experience Rapid Growth due to Supportive Governments 

In the forecast period, North America is expected to account for a substantial share in the uveitis drugs market. The elevated incidence of related uveitis risk factors coupled with anticipated product approvals will lead to the increase in the uveitis drugs market in this region. 

Asia Pacific, due to the greater incidence of uveitis in this region, is anticipated to experience the a swift growth of the uveitis drugs market during the forecasted era. A number of governments and private organizations have taken measures to raise disease awareness and to provide patients in the region with several therapy alternatives.

The study presents a granular assessment and quantitative evaluation of:

  • Key growth factors and prominent trends
  • Size and share of key segments in overall market
  • Key challenges and winning imperatives
  • Factors shaping competitive landscape
  • Insights into how contours of market will change in coming years
  • Technological advances
  • New avenues and imminent investment pockets
  • Regulatory landscape shaping current and future strategies of companies

The region-wise assessment includes market dynamics in:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study is prepared with the help of an extensive primary and secondary research. Primary research includes but not limited to interactions, interviews, surveys, and events. Opinions of policy makers and industry experts are carefully integrated into the insights to complement primary research. Volumes of secondary data gleaned through renowned paid sources, annual statements, reputed journals, and government documents offer insights into current dynamics and key evolution trajectories the market is likely to assume. The research employs various industry-wide analytics methods and well-established methodologies to ascertain the attractiveness of key segments. Further, it evaluates the lucrativeness of key regions and factors underlying their maturity. The insights notably include a detailed analysis of forces behind vendor differentiation and offers insight into investment-decision making by prominent players.

The report strives to enlighten businesses and industry stakeholders on multiple facets of the growth dynamic of the market, the key of which include answers to:

  • Which key factors will shape the competitive landscape?
  • Which trends will stimulate research and development activities in different geographies?
  • Which are the lucrative growth areas and what is the size of potential they are likely contribute to the overall market?
  • Which disruptions in market growth are likely to come with the new business models?
  • Which are some of the recent overhauls in policies that may change the course of the market significantly?
  • Which are the geographies that will form sizable sources of new streams to new and established players alike?
  • How are top players likely to realign their strategy to counter the forces of competition?
  • Which key strategies emerging players are likely to focus on to consolidate their position?
  • Which changes in end-user preferences might affect the status quo held by the leading players?
  • Which are some of the game-changing innovations influencing the projected share and revenue of the market and its segments?

Note: Utmost care has invariably been taken to present data and arrive at statistics at all the TMR Research reports. Meanwhile, some recent developments and new industry trends may take time to be included in the reports.

Wish to check Table of Contents of this report?

Click below to Request TOC

Request TOC